M&A Deal Summary

Eight Roads and Lupin Acquire Symbiomix Therapeutics

On October 11, 2017, private equity firm Eight Roads and Lupin acquired life science company Symbiomix Therapeutics for 150M USD

Acquisition Highlights
  • This is Eight Roads’ 47th and Lupin’s 7th transaction in the Life Science sector.
  • This is Eight Roads’ and Lupin’s largest (disclosed) transaction.
  • This is Eight Roads’ 80th and Lupin’s 3rd transaction in the United States.
  • This is Eight Roads’ 2nd and Lupin’s 3rd transaction in New Jersey.

M&A Deal Summary
Date 2017-10-11
Target Symbiomix Therapeutics
Sector Life Science
Buyer(s) Eight Roads
Lupin
Deal Type Add-on Acquisition
Deal Value 150M USD

Target

Symbiomix Therapeutics

Newark, New Jersey, United States
Symbiomix Therapeutics is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. Symbiomix Therapeutics was founded in 2012 and is based in Newark, New Jersey.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 2

Buyer

Eight Roads

Investor

Category Private Equity Firm
Founded 1969
Size Small
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 168 of 298
Sector (Life Science) 47 of 74
Type (Add-on Acquisition) 1 of 1
State (New Jersey) 2 of 4
Country (United States) 80 of 124
Year (2017) 32 of 40
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-10-03 Dimension Therapeutics

Cambridge, Massachusetts, United States

Dimension Therapeutics is a developer of new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.

Sell $151M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-10-17 BankBazaar.com

Chennai, India

BankBazaar.com is India’s fintech co-branded credit card issuer and online platform for free credit score. BankBazaar.com was founded in 2008 and is based in Chennai, India.

Buy -
Buyer

Lupin

Mumbai, India
Category Company
Founded 1968
Sector Life Science
Employees19,210
Revenue 196.6B INR (2024)
DESCRIPTION

Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, India.

DEAL STATS #
Overall 8 of 9
Sector (Life Science) 7 of 8
Type (Add-on Acquisition) 6 of 6
State (New Jersey) 3 of 3
Country (United States) 3 of 4
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-09 GAVIS Pharmaceuticals

Somerset, New Jersey, United States

GAVIS Pharmaceuticals LLC is a provider of pharmaceutical products in a variety of dosage forms.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-11 Kyowa Pharmaceutical

Osaka, Japan

Kyowa Pharmaceutical is a generic pharmaceutical company and is the domestic provider in the Central Nervous System (CNS) therapeutic area. Kyowa Pharmaceutical was founded in 1954 and is based in Osaka, Japan.

Sell -
Mergr

Product

Company

Legal